<DOC>
	<DOCNO>NCT00620282</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The purpose trial ass effect liraglutide forearm blood flow subject type 2 diabetes diet lifestyle change treat metformin alone .</brief_summary>
	<brief_title>The Effect Liraglutide Endothelial Function Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes Diet lifestyle change metformin monotherapy least three month HbA1c ( glycosylated haemoglobin ) 6.59.0 % ( inclusive ) Body Mass Index ( BMI ) less equal 40 kg/m^2 Previous treatment insulin ( except short term treatment insulin connection intercurrent illness , discretion Investigator ) Previous treatment glucagonlike peptide1 ( GLP1 ) analogues/mimetics , include treatment clinical trial Treatment oral hypoglycaemic agent metformin period 3 month prior screen Current smoker history smoking within 6 month prior screen Evidence overt cardiovascular disease ( document coronary heart disease , class IIIV congestive heart failure , cerebrovascular disease , peripheral vascular disease ) Abnormal , clinically significant exercise stress electrocardiogram ( ECG ) test , judge Investigator Known retinopathy maculopathy require acute treatment , judge Investigator Known autonomic neuropathy , judge Investigator Initiation change ( dose treatment regimen ) concomitant blood pressurelowering lipidlowering medication within 4 week prior screen Systolic blood pressure equal 140 mmHg and/or diastolic blood pressure equal 90 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>